- Home
- RQI vs ARQT Comparison
RQI vs ARQT Comparison
Compare RQI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- ARQT
- Stock Information
- Founded
- RQI 2002
- ARQT 2016
- Country
- RQI United States
- ARQT United States
- Employees
- RQI N/A
- ARQT N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- RQI Finance
- ARQT Health Care
- Exchange
- RQI Nasdaq
- ARQT Nasdaq
- Market Cap
- RQI 1.7B
- ARQT 1.7B
- IPO Year
- RQI N/A
- ARQT 2020
- Fundamental
- Price
- RQI $12.37
- ARQT $13.53
- Analyst Decision
- RQI
- ARQT Strong Buy
- Analyst Count
- RQI 0
- ARQT 6
- Target Price
- RQI N/A
- ARQT $18.80
- AVG Volume (30 Days)
- RQI 432.6K
- ARQT 2.1M
- Earning Date
- RQI 01-01-0001
- ARQT 05-06-2025
- Dividend Yield
- RQI 8.20%
- ARQT N/A
- EPS Growth
- RQI N/A
- ARQT N/A
- EPS
- RQI N/A
- ARQT N/A
- Revenue
- RQI N/A
- ARQT $212,819,000.00
- Revenue This Year
- RQI N/A
- ARQT $57.99
- Revenue Next Year
- RQI N/A
- ARQT $41.24
- P/E Ratio
- RQI N/A
- ARQT N/A
- Revenue Growth
- RQI N/A
- ARQT 100.03
- 52 Week Low
- RQI $9.17
- ARQT $6.99
- 52 Week High
- RQI $12.64
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- RQI 57.16
- ARQT 42.73
- Support Level
- RQI $12.21
- ARQT $12.42
- Resistance Level
- RQI $12.55
- ARQT $15.67
- Average True Range (ATR)
- RQI 0.20
- ARQT 0.84
- MACD
- RQI 0.07
- ARQT -0.07
- Stochastic Oscillator
- RQI 82.00
- ARQT 34.15
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.